恩替卡韦治疗对慢性乙型肝炎患者免疫状况的影响。

StephenW

Iran J Immunol. 2019 Mar;16(1):84-91. doi: 10.22034/IJI.2019.39409.
The Effect of Entecavir Therapy on Immune Status in Chronic Hepatitis B Patients.
Yan H1, Zhang X, Lv Y.
Author information

1
    Clinical Research Center, Shijiazhuang Fifth Hospital, Shijiazhuang, Hebei 050021, China.

Abstract
BACKGROUND:

Entecavir (ETV) is an antiviral medication effective in suppressing hepatitis B virus (HBV) replication and improving liver function. However, the relationship between antiviral effect and immune modulation after ETV therapy is not clearly understood.
OBJECTIVE:

The objective of this study is to investigate the immunoregulatory effect of ETV treatment in patients with chronic hepatitis B (CHB).
METHODS:

The frequencies of immune cells, including IFN-γ-producing CD4+ and CD8+ T cells, Th9 cells, regulatory T (Treg) cells, and myeloid-derived suppressor cells (MDSC) were determined in the peripheral blood from treatment-naïve and ETV-treated CHB patients. The plasma levels of IL-10, TGF-β, IL-9, TNF-α, IFN-γ, and Arg-1 were measured using enzyme-linked immunosorbent assay.
RESULTS:

The results showed that ETV treatment significantly reduced the levels of liver function indices as well as HBV DNA loads in CHB patients. However, no significant difference in the immune cells percentage was found between the treatment-naïve and ETV-treated patients. Additionally, ETV treatment did not influence the production of TGF-β, IL-9, Arg-1, IFN-γ, and TNF-α. In contrast, the level of IL-10 was remarkably reduced after ETV therapy.
CONCLUSION:

IL-10 was a more sensitive effector to ETV-induced inhibition of HBV replication in chronic HBV patients.

PMID:
    30864558
DOI:
    10.22034/IJI.2019.39409

StephenW

伊朗J Immunol。 2019年3月; 16（1）：84-91。 doi：10.22034 / IJI.2019.39409。
恩替卡韦治疗对慢性乙型肝炎患者免疫状况的影响。
严H1，张,,吕Y.
作者信息

1
    石家庄市第五医院临床研究中心，河北石家庄050021

抽象
背景：

恩替卡韦（ETV）是一种有效抑制乙型肝炎病毒（HBV）复制和改善肝功能的抗病毒药物。然而，ETV治疗后抗病毒效应与免疫调节之间的关系尚不清楚。
目的：

本研究的目的是研究ETV治疗慢性乙型肝炎（CHB）患者的免疫调节作用。
方法：

免疫细胞的频率，包括产生IFN-γ的CD4 +和CD8 + T细胞，Th9细胞，调节性T（Treg）细胞和骨髓衍生的抑制细胞（MDSC）在来自未治疗的外周血和ETV-中测定。治疗的CHB患者。用酶联免疫吸附试验测定血浆中IL-10，TGF-β，IL-9，TNF-α，IFN-γ和Arg-1的水平。
结果：

结果显示，ETV治疗显着降低了CHB患者的肝功能指标水平以及HBV DNA载量。然而，在未接受治疗和ETV治疗的患者之间未发现免疫细胞百分比的显着差异。另外，ETV治疗不影响TGF-β，IL-9，Arg-1，IFN-γ和TNF-α的产生。相反，ETV治疗后IL-10水平显着降低。
结论：

IL-10是ETV诱导的慢性HBV患者HBV复制抑制的更敏感的效应物。

结论：
    30864558
DOI：
    10.22034 / IJI.2019.39409